Detheux Michel

CEO Michel Detheux sold 104.6K shares for $1.0M (blended avg $10.02) on Jun 9–10, reducing stake by 52.7%

Detheux executed 4 separate sales totaling 104,565 shares for $1,048,264.12 at an average price of $10.02, cutting his holding from 198,592 shares to 94,027 shares—a 52.7% reduction. The timing is notable: the stock was trading at $10.00 on the filing date, approximately 44.4% below its 52-week high of $17.97, and had rallied 44.5% over the prior 30 days. Detheux's prior trades at ITOS (5 recent sales from June 4–6) do not yet have measurable 30-day or 90-day outcomes, so comparison to his same-ticker history is not yet possible. The underlying company is unprofitable with a net loss of $34,613,000 in the latest full year, though it reported annual revenue growth of 177.9%, positioning this transaction amid a financially volatile period for the firm.

CEO Detheux Michel sells entire 156,847-share stake in ITOS for $1.6M across 6 transactions (Jun 4–6)

Michel, iTeos' Chief Executive Officer, executed 6 separate sales totaling 156,847 shares for $1,592,519.82 between June 4–6, 2025, at prices ranging from $10.10 to $10.21 (blended average $10.15), eliminating his entire shareholding from 156,847 shares to zero. The company is unprofitable with net income of $-34,613,000.00 and latest-quarter revenue of $0.00, despite posting annual revenue growth of +177.9%, suggesting the firm is in a pre-commercial or early-stage therapeutic development phase. The stock's 52-week range of $5.04–$17.97 indicates volatility; the current price of $10.17 sits -43.4% from the 52-week high and +57.9% above its 30-day level, placing the sale near recent strength but well below peak valuations. A CEO's complete exit from equity ownership at a biotech with negative earnings and minimal revenue raises material questions about leadership confidence or personal liquidity needs, especially given the absence of any offsetting purchases or indication of scheduled plan activity.